Rhenman & Partners Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Rhenman & Partners Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-62,517	Closed	-$3.01M	–	97
2015 Q1	$3.01M	Hold	62,517	–	–	0.51%	68
2014 Q4	$2.08M	Hold	62,517	–	–	0.6%	73
2014 Q3	$1.83M	Sell	62,517 -4,809	-7%	-$160K	0.54%	80
2014 Q2	$2.62M	Buy	67,326 +3,900	+6%	+$158K	0.78%	48
2014 Q1	$2.66M	Buy	63,426 +2,512	+4%	+$105K	0.8%	46
2013 Q4	$2M	Buy	+60,914	New	+$1.98M	0.78%	58

Other funds holding LGND

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rhenman & Partners Asset Management's LGND Position: Q2 2015 in Review

Rhenman & Partners Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2015, closing a stake of 62,517 shares — an estimated $3.01M sold.

Rhenman & Partners Asset Management first reported a position in LGND in Q4 2013 and held it in 6 quarters. The position peaked at $3.01M in Q1 2015. 215 funds tracked by Wall St. Rank hold LGND as of Q2 2015.

Rhenman & Partners Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Rhenman & Partners Asset Management sold 62,517 Ligand Pharmaceuticals shares in Q2 2015, an estimated $3.01M.
Rhenman & Partners Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Rhenman & Partners Asset Management's Ligand Pharmaceuticals position peaked at $3.01M in Q1 2015.
215 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2015.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2015, filed 30 Jul 2015.